Physician profile
Jon M Bruce
NPI 1659306819
$84,542.83
in general payments reported to CMS, 2019-2025
22 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,258 · 2020: $19K · 2021: $12K · 2022: $41K · 2023: $8,405 · 2024: $426 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,314 · Food and Beverage: $1,385 · Travel and Lodging: $402 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,314.03 |
| Food and Beverage | $1,385.28 |
| Travel and Lodging | $402.01 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $63,424.93 | 2019-2023 | Echelon Flex, Echelon Endopath |
| Intuitive Surgical, INC. | $15,577.51 | 2019-2023 | Da Vinci Surgical System |
| Ethicon US, LLC | $2,439.23 | 2019-2023 | Echelon; Endopath |
| Abbvie INC. | $923.55 | 2019-2025 | |
| Novo Nordisk INC | $868.69 | 2021-2025 | Wegovy, Saxenda |
| W. L. Gore & Associates, INC. | $371.24 | 2021 | |
| Medtronic, INC. | $312.67 | 2022-2023 | Signia |
| Axogen | $143.51 | 2023 | Avance Nerve Graft |
| Aesculap, INC. | $127.89 | 2019 | |
| Resmed Corp | $58.28 | 2020 | |
| Abbott Laboratories | $53.45 | 2019 | |
| Currax Pharmaceuticals LLC | $33.78 | 2023-2024 | Contrave |
| Heron Therapeutics, INC. | $33.69 | 2022 | |
| Aimmune Therapeutics, INC. | $32.47 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.51 | 2024 | Gattex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $21.32 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lucid Diagnostics INC. | $21.17 | 2023 | |
| Eagle Pharmaceuticals, INC. | $19.87 | 2024 | |
| Davol INC. | $18.06 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $16.01 | 2019 | |
| Merck Sharp & Dohme LLC | $12.80 | 2019 | |
| Covidien LP | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.